Zoetis received a conditional license from the United States Department of Agriculture (USDA), Center for Veterinary Biologics (CVB), for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus for use in chickens. Our scientists routinely update our vaccines, and they began working on an updated Highly Pathogenic Avian Influenza (HPAI) vaccine in 2022 when a new strain was identified in the U.S. Zoetis’ Avian Influenza Vaccine, H5N2 Subtype, Killed Virus was designed to closely match the currently circulating highly pathogenic H5 avian influenza and has demonstrated a reasonable expectation of efficacy against current H5N1 strains. The N2 designation is utilized as a tool to differentiate vaccinated birds from naturally infected birds. The decision to vaccinate commercial poultry flocks rests solely with national regulatory authorities in consultation with their local poultry sector. Zoetis has several decades of experience developing vaccines for avian influenza in multiple countries and remains committed to supporting poultry producers by providing scientific solutions for HPAI.